Clinical Trial

Testing Experimental Frontotemporal Dementia Medication

Study Description

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin Mutation

A first in human phase 1 study in healthy volunteers and participants with Granulin mutation causative of frontotemporal dementia (FTD) to assess AL001 safety, tolerability, pharmacokinetics, and pharmacodynamics

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Biological - AL001

Active dose of AL001

Placebo

Saline solution administered as a single infusion as palcebo.

Additional Information

Official Study Title

A First in Human Phase 1 Study in Healthy Volunteers and in Participants With Frontotemporal Dementia (FTD) With Granulin Mutation

Clinical Trial ID

NCT03636204

ParticipAid ID

bkRZNa